BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 10517729)

  • 1. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
    Antman EM; McCabe CH; Gurfinkel EP; Turpie AG; Bernink PJ; Salein D; Bayes De Luna A; Fox K; Lablanche JM; Radley D; Premmereur J; Braunwald E
    Circulation; 1999 Oct; 100(15):1593-601. PubMed ID: 10517729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
    Antman EM; Cohen M; Radley D; McCabe C; Rush J; Premmereur J; Braunwald E
    Circulation; 1999 Oct; 100(15):1602-8. PubMed ID: 10517730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.
    Antman EM
    Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S353-60. PubMed ID: 9628449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
    Goodman SG; Cohen M; Bigonzi F; Gurfinkel EP; Radley DR; Le Iouer V; Fromell GJ; Demers C; Turpie AG; Califf RM; Fox KA; Langer A
    J Am Coll Cardiol; 2000 Sep; 36(3):693-8. PubMed ID: 10987586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
    Antman EM; Cohen M; Bernink PJ; McCabe CH; Horacek T; Papuchis G; Mautner B; Corbalan R; Radley D; Braunwald E
    JAMA; 2000 Aug; 284(7):835-42. PubMed ID: 10938172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
    Cohen M; Théroux P; Borzak S; Frey MJ; White HD; Van Mieghem W; Senatore F; Lis J; Mukherjee R; Harris K; Bigonzi F;
    Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
    Antman EM; Louwerenburg HW; Baars HF; Wesdorp JC; Hamer B; Bassand JP; Bigonzi F; Pisapia G; Gibson CM; Heidbuchel H; Braunwald E; Van de Werf F
    Circulation; 2002 Apr; 105(14):1642-9. PubMed ID: 11940541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators.
    J Am Coll Cardiol; 1997 Jun; 29(7):1474-82. PubMed ID: 9180107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time.
    Bozovich GE; Gurfinkel EP; Antman EM; McCabe CH; Mautner B
    Am Heart J; 2000 Oct; 140(4):637-42. PubMed ID: 11011339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
    Berkowitz SD; Stinnett S; Cohen M; Fromell GJ; Bigonzi F;
    Am J Cardiol; 2001 Dec; 88(11):1230-4. PubMed ID: 11728348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
    Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
    J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
    Collet JP; Montalescot G; Fine E; Golmard JL; Dalby M; Choussat R; Ankri A; Dumaine R; Lesty C; Vignolles N; Thomas D
    J Am Coll Cardiol; 2003 Jan; 41(1):8-14. PubMed ID: 12570937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
    Fox KA; Antman EM; Cohen M; Bigonzi F;
    Am J Cardiol; 2002 Sep; 90(5):477-82. PubMed ID: 12208405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
    Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
    Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
    Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.
    Turpie AG
    Can J Cardiol; 1998 Aug; 14 Suppl E():20E-23E. PubMed ID: 9779029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxaparin. A review of its clinical potential in the management of coronary artery disease.
    Noble S; Spencer CM
    Drugs; 1998 Aug; 56(2):259-72. PubMed ID: 9711450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
    Demers C
    Can J Cardiol; 1998 Aug; 14 Suppl E():15E-19E. PubMed ID: 9779028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.